



## Announcement Summary

---

**Entity name**

BIONOMICS LIMITED

**Announcement Type**

New announcement

**Date of this announcement**

Tuesday June 2, 2020

**The Proposed issue is:**

☒ A placement or other type of issue

**Total number of +securities proposed to be issued for a placement or other type of issue**

ASX +Security Code	+Security Description	Maximum Number of +securities to be issued
BNO	ORDINARY FULLY PAID	135,833,000

**Proposed +issue date**

Monday June 15, 2020

Refer to next page for full details of the announcement



## Part 1 - Entity and announcement details

---

### 1.1 Name of +Entity

BIONOMICS LIMITED

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

### 1.2 Registered Number Type

ABN

### Registration Number

53075582740

### 1.3 ASX issuer code

BNO

### 1.4 The announcement is

☒ New announcement

### 1.5 Date of this announcement

Tuesday June 2, 2020

### 1.6 The Proposed issue is:

☒ A placement or other type of issue



## Part 7 - Details of proposed placement or other issue

### Part 7A - Conditions

#### 7A.1 - Are any of the following approvals required for the placement or other type of issue?

- +Security holder approval
- Court approval
- Lodgement of court order with +ASIC
- ACCC approval
- FIRB approval
- Another approval/condition external to the entity

☒ Yes

#### 7A.1a Conditions

Approval/Condition	Date for determination	Is the date estimated or actual?	** Approval received/condition met?
FIRB approval	Monday August 10, 2020	<input checked="" type="checkbox"/> Estimated	No

#### Comments

Shareholder and FIRB approval required for Second Placement, underwriting arrangements and issue of Warrants. Refer to announcement dated 2 June 2020.

No approval required for First Placement as described in announcement dated 2 June 2020.

### Part 7B - Issue details

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?

☒ Existing class

Will the proposed issue of this +security include an offer of attaching +securities?

☒ No

#### Details of +securities proposed to be issued

##### ASX +Security Code and Description

BNO : ORDINARY FULLY PAID

##### Maximum Number of +securities proposed to be issued

135,833,000



### Purpose of the issue

Fund Clinical Trial & working capital.  
First Placement\* - 81,500,000 (within placement capacity)  
Second Placement\* - 54,333,000  
Underwriting arrangements\* £ up to 250,000,000  
Warrants\* £ 150,000,000 (convertible into 150,000,000 fully paid ordinary shares)  
\* in this Part 7B the above expressions are used as described in announcement dated 2 June 2020

### Offer price details for retail security holders

<b>In what currency is the cash consideration being paid?</b>	<b>What is the issue price per +security?</b>
AUD - Australian Dollar	AUD 0.04000

**Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?**

☒ Yes

### Oversubscription & Scale back details

**May a scale back be applied to this event?**

☒ No

---

## Part 7C - Timetable

### 7C.1 Proposed +issue date

Monday June 15, 2020

---

## Part 7D - Listing Rule requirements

**7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1?**

☒ Yes

**7D.1a Date of meeting or proposed meeting to approve the issue under listing rule 7.1**

Monday August 10, 2020

**7D.2 Is a party referred to in listing rule 10.11.1 participating in the proposed issue?**

☒ No

**7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules?**

☒ No



---

**7D.4 Will any of the +securities to be issued be subject to +voluntary escrow?**

☒ No

Part 7E - Fees and expenses

---

**7E.1 Will there be a lead manager or broker to the proposed issue?**

☒ No

**7E.2 Is the proposed issue to be underwritten?**

☒ No

**7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue**

In relation to shares issued pursuant to the underwriting arrangements described in the announcement dated 2 June 2020, the principal material cost will be the issue of the Warrants referred to elsewhere in this Appendix 3B

Part 7F - Further Information

---

**7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds?**

☒ No

**7F.2 Any other information the entity wishes to provide about the proposed issue**

No approval required the First Placement\*  
Approval required for the Second Placement\*  
Further shareholder approvals are to be sought in relation to the Warrants and the underwriting arrangements\*  
Refer to announcement dated 2 June 2020